Radiation oncology firm Accuray's long-time CEO Euan Thomson, PhD, has resigned, and in his place the company has appointed Joshua Levine as president and CEO.
Saying it was time for a change in leadership at the company, Thomson thanked colleagues for their support over his 10-year tenure, during which Accuray introduced its flagship CyberKnife product. Accuray's acquisition of TomoTherapy in 2011 expanded the company into the radiotherapy market.
Last month the company reported that its net loss for fiscal 2012 had more than doubled from the previous fiscal year, from $27.1 million to $78.5 million, as full-year revenues grew to $409.2 million, compared with $222.3 million in fiscal 2011.
Thomson's successor, Levine, was CEO of Mentor, where he led the company through a strategic transformation and was a key player in its sale to a franchise of Johnson & Johnson in 2009, Accuray said. More recently, Levine was CEO of Immucor until last October, when it was purchased by TPG Capital.
